Intervention Review

You have free access to this content

Haloperidol dose for the acute phase of schizophrenia

  1. Lorna Donnelly1,*,
  2. John Rathbone2,
  3. Clive E Adams3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 28 AUG 2013

Assessed as up-to-date: 2 FEB 2010

DOI: 10.1002/14651858.CD001951.pub2


How to Cite

Donnelly L, Rathbone J, Adams CE. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD001951. DOI: 10.1002/14651858.CD001951.pub2.

Author Information

  1. 1

    NHS Lothian, Cambridge Street House, Edinburgh, Lothian, UK

  2. 2

    The University of Sheffield, HEDS, ScHARR, Sheffield, UK

  3. 3

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

*Lorna Donnelly, Cambridge Street House, NHS Lothian, 5-7 Cambridge Street, Edinburgh, Lothian, EH1, UK. lornadonnelly@doctors.org.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 28 AUG 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Curtis 1995 {published data only}
  • Curtis CE, Mann M, Piscani K, Burr G, Hitzemann RJ, Hirschowitz J. A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami. 1995.
Donlon 1980 {published data only}
  • Donlon PT, Hopkin JT, Tupin JP, Wicks JJ, Wahba M, Meadow A. Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of General Psychiatry 1980;6:691-5.
  • Wahba M, Donlon PT, Meadow A. Cognitive changes in acute schizophrenia with brief neuroleptic treatment. American Journal of Psychiatry 1981;138(10):1307-10.
Janicak 1997 {published data only}
Kapur 2000 {published data only}
  • Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 2000;4:514-20.
Khanna 1997 {published data only}
  • Khanna A, Lal N, Dalal PK, Khalid A, Trivedi JK. Treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol. Indian Journal of Psychiatry 1997;39(2):136-42.
Klieser 1987 {published data only}
  • Klieser E, Lehmann E. Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol. Neuropsychobiology 1987;18(3):122-6.
  • Klieser E, Lehmann E. Experimental comparison of the efficacy of standardized haloperidol treatment and adequate individual dosages in acute schizophrenic states. Fortschritte der Neurologie Psychiatrie 1992;3:126-9.
Liang 1987 {published data only}
  • Liang S. Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol. Chinese Journal of Neurology and Psychiatry 1987;20(1):43-8.
Louza 1988 {published data only}
  • Louza Neto MR, Muller Spahn F, Ruther E, Scherer J. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry 1988;21(5):226-31. [MEDLINE: 3227054]
McEvoy 1991 {published data only}
Modestin 1983 {published data only}
  • Modestin J, Toffler G, Pia M, Greub E. Haloperidol in acute schizophrenic inpatients. A double-blind comparison of two dosage regimens. Pharmacopsychiatria 1983;16:4121-6.
Neborsky 1981 {published data only}
  • Neborsky R, Depry D, Janowsky DS, Munson E, Perel J. Haloperidol plasma red blood-cell ratios and clinical efficacy. Psychopharmacology Bulletin 1982;18(4):17-20.
  • Neborsky R, Janowsky D, Munson E, Depry D. Rapid treatment of acute psychotic symptoms with high-and low-dose haloperidol. Behavioral considerations. Archives of General Psychiatry 1981;38(2):195-9.
  • Neborsky R, Janowsky D, Munson E, Hornbeck C, Depry D. Behavioral prediction of response to haloperidol: a test dose strategy. Journal of Clinical Psychiatry 1982;43(4):157-8.
  • Neborsky RJ, Janowsky DS, Perel JM. Red-blood-cell plasma haloperidol ratios and antipsychotic efficacy. Psychiatry Research 1982;6(1):123-4.
  • Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry 1984;45(1):10-3.
Oosthuizen 2004 {published data only}
  • Oosthuizen P, Emsley R, Turner HJ, Keyter N. A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. International Journal of Neuropsychopharmacology 2004;7(2):125-31. [MEDLINE: 15003147]
Palao 1994 {published data only}
  • Palao DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, et al. Haloperidol: therapeutic window in schizophrenia. Journal of Clinical Psychopharmacology 1994;14(5):303-10.
  • Palao DJ, Arauxo A, Brunet M, Marquez M, Bernardo M, Ferrer J, et al. Positive versus negative symptoms in schizophrenia: response to haloperidol. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1994;18(1):155-64.
  • Palao DJ, Arauxo A, Haro JM, Brunet M, Bernardo M, Volavka J, et al. The relationship between plasma haloperidol concentrations and clinical results. Archives of General Psychiatry 1996;53(12):1167-9.
Rifkin 1991 {published data only}
Simpson 1967 {published data only}
  • Simpson GM, Angus JWS, Edwards JG. A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research 1967;9(8):401-12.
Stone 1995 {published data only}
Volavka 1992 {published data only}
  • Bitter I, Volavka J, Cooper J, Scheurer, Camus L, Bakall R. Haloperidol blood levels and clinical effects in schizophrenia. Proceedings of the 8th World Congress of Psychiatry; 1989 Oct 13-19; Athens, Greece. 1989.
  • Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research 1998;81(1):51-5.
  • Convit A, Volavka J, Czobor P, De Asis J, Evangelista C. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. American Journal of Psychiatry 1994;151(1):49-56.
  • Cooper TB, Volavka J, Czobor P. Plasma drug level and clinical response. Journal of Clinical Psychopharmacology 1992;12(2):134-6.
  • Czobor P, Volavka J. Dimensions of the brief psychiatric rating scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry 1996;37(3):205-15.
  • Czobor P, Volavka J. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Research 1992;42(2):129-44.
  • Czobor P, Volavka J. Positive and negative symptoms: is their change related?. Schizophrenia Bulletin 1996;22(4):577-90.
  • Czobor P, Volavka J. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology 1993;13(5):332-42.
  • Krakowski M, Czobor P, Volavka J. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Research 1997;71(1):19-26.
  • Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al. Haloperidol blood levels and clinical effects. Archives of General Psychiatry 1992;5:354-61.
  • Volavka J, Cooper TB, Meisner M, Bitter I, Czobor P, Jaeger J. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacology Bulletin 1990;26(1):13-7.
  • Volavka J, Douyon R, Convit A, Czobor P, Cooper TB. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited. Archives of General Psychiatry 1992;49(12):999-1000. [MEDLINE: 1449388]
Volavka 1995 {published data only}
  • Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research 1998;81(1):51-5.
  • Czobor P, Volavka J. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry 1996;37(3):205-15.
  • Czobor P, Volavka J. Positive and negative symptoms: is their change related?. Schizophrenia Bulletin 1996;22(4):577-90.
  • Volavka J, Cooper TB, Czobor P, Meisner M. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacology Bulletin 1996;32(1):75-9.
  • Volavka J, Cooper TB, Czobor P, Meisner M. Haloperidol plasma levels and clinical effects. Psychopharmacology Bulletin 1995;31:536.
  • Volavka J, Cooper TB, Czobor P, Meisner M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry 1995;52(10):837-45.
Winter 1984 {published data only}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Bjorndal 1980 {published data only}
  • Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 1980;67(1):17-23.
Boyer 1987 {published data only}
  • Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique ses neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie 1987;2(4):296-305.
Coryell 1990 {published data only}
Coryell 1998 {published data only}
Davis 1985 {published data only}
  • Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, et al. Blood levels of haloperidol and clinical response. Psychopharmacology Bulletin 1985;21(1):48-51.
  • Ericksen SE, Hurt SW, Chang S. Haloperidol dose, plasma levels, and clinical response: a double-blind study. Psychopharmacology Bulletin 1978;14(2):15-6.
  • Hurt SW, Holzma PS, Davis JM. Thought disorder. The measurement of its changes. Archives of General Psychiatry 1983;40:1281-5.
Dubin 1985 {published data only}
  • Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Petrone C. Rapid tranquilization: the efficacy of oral concentrate. Journal of Clinical Psychiatry 1985;46(11):475-8.
Dutoit 1995 {published and unpublished data}
  • Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, et al. Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses [Activite cetone reductase erythrocytaire, taux plasmatiques d'haloperidol et psychoses aigues]. Encephale 1995;21(6):417-24.
Garver 1984 {published data only}
Garver 1985 {published data only}
  • Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML. Haloperidol plasma and red blood cell levels and clinical antipsychotic response. Journal of Clinical Psychopharmacology 1984;4(3):133-7.
Gerlach 1985a {published data only}
  • Gerlach J, Behnke K, Heltberg J, Munk-Andersen, Nielsen H. Dogmatil and haloperidol for the treatment of schizophrenia. Double blind cross-over study of therapeutic effectiveness, side effects and plasma concentrations [Le dogmatil et l'haloperidol dans le traitement de la schizophrenie. Etude croisee en double aveugle de l'action therapeutique, des effets secondaires et des concentrations plasmatiques]. Semaine des Hopitaux 1985;61(19):1309-16.
Hirschowitz 1997 {published data only}
Levin 1996 {published data only}
Ortega-Soto 1993 {published data only}
  • Ortega-Soto HA, Fernandez AE, Pinedo H, De La Torre P, Brunner E, Apiquian R. Clinical trial of haloperidol threshold doses. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco. 1993.
Ortega-Soto 1994 {published data only}
  • Ortega-Soto HA, Brunner E, Apiquian R, De La Torre P. Therapeutic minimum dose of haloperidol in schizophrenia. Neuropsychopharmocology 1994;10(3S Pt 2):140S.
  • Ortega-Soto HA, Fernandez AE, Pinedo H, De La Torre P, Brunner E, Apiquian R. Clinical trial of haloperidol threshold doses. Patient Care for the 21st Century: Asserting Professional Values with Economic Restraints. Proceedings of the 146th Annual Meeting of the American Psychiatric Association; 1993, May 22-27; San Francisco. 1993.
Reschke 1974 {published data only}
Santos 1989 {published data only}
Sim 1989 {published data only}
  • Sim CB, Lee YC, Hwang JP. Haloperidol for schizophrenic inpatients with three doseage regimens. Psychiatry Today: Accomplishments and Promises; Proceedings of the 8th World Congress of Psychiatry; 1989, Oct 12-19; Athens, Greece. London: Excerpta Medica International Congress Series 899, 1989:817.
Smith 1984 {published data only}
  • Smith RC. Plasma haloperidol levels-clinical-response and fancy mathematics - reply. Archives of General Psychiatry 1985;42(8):835-8.
  • Smith RC. The interpretation of plasma haloperidol concentrations-reply. Archives of General Psychiatry 1985;42(8):839-40.
  • Smith RC, Baumgartner R, Burd A, Calderon M, Largen J, Mauldin M, et al. Cortical atrophy and white matter density in the brains of schizophrenics and clinical-response to neuroleptics. Acta Psychiatrica Scandinavica 1987;75(1):11-9.
  • Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, et al. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Archives of General Psychiatry 1984;41(11):1044-9.
  • Smith RC, Burd A, Baumgartner R, Ravichandran GK, Mauldin M. Haloperidol and thioridazine drug levels and clinical-response in schizophrenia-comparison of gas-liquid-chromatography and radioreceptor drug level assays. Psychopharmacology Bulletin 1985;21(1):52-8.
  • Smith RC, Ravichandran GK, Vroulis G, Mauldin M, Baumgartner R, Gordon J, et al. Lateral ventricular enlargement and clinical-response in schizophrenia. Psychiatry Research 1985;14(3):241-53.
  • Smith RC, Shvartsburd A, Vroulis G, Ravichandran GK, Mauldin M, Baumgartner R. Comparative efficacy of red-cell and plasma haloperidol as predictors of clinical-response in schizophrenia. Psychopharmacology 1985;85(4):449-55.
Smith 1987 {published data only}
Van Putten 1990 {published data only}
Volavka 2000 {published data only}
  • Volavka J, Cooper TB, Czobor P, Lindenmayer J P, Citrome LL, Mohr P, et al. High dose treatment with haloperidol: the effect of dose reduction. Journal of Clinical Psychopharmacology 2000;20(2):252-6. [MEDLINE: 10770466]
  • Volavka J, Cooper TB, Czobor P, Lindenmayer JP, Citrome LL, Mohr P. Haloperidol blood levels and effects in schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego. 1997.
Zimbroff 1997 {published data only}
  • Baker R, Mack R, Morris D, Sebree T, Kashkin KB. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands. 1996.
  • Bark N, Mack R, Zborowski J, Morris D, Sebree T, Shook S, et al. Efficacy and safety of three doses of sertindole and haloperidol in schizophrenic patients. Biological Psychiatry 1996;39:597.
  • Larson GL, Mack RJ, Zborowski J, Morris DD, Sebree TB, Wallin BA. Three doses each of sertindole and haloperidol in schizophrenics. Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain. 1996.
  • Tamminga C, Mack R, Zborowski J, Morris D, Sebree T, Wallin B. Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996.
  • Zimbroff DL, Kane JM, Tamminga C, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole study group. American Journal of Psychiatry 1997;154(6):782-91.
  • Zimbroff DL, Mack RJ, Morris DD, Silber CJ. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Schizophrenia 1996: Breaking Down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver. 1996.
  • Zimbroff DL, Mack RJ, Zborowski JN, Morris DD, Sebree TB, Wallin BA. The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York. 1996.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Addington 1990
Altman 1996
APA 1997
  • American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 1997;154 Suppl 4:1-63.
Awad 1993
  • Awad AG. Methodological and design issues in clinical trials of new neuroleptics: an overview. British Journal of Psychiatry 1993;Suppl 22:51-7.
Awad 1999
Bagnall 2002
  • Bagnall, A-M. Lewis, RA. Leitner, ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001945]
Baldessarini 1984
Baldessarini 1988
Baldessarini 1995
  • Baldessarini RJ, Kando JC, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. American Journal of Psychiatry 1995;152(7):1038-44.
Bezchlibnyk 1994
  • Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Canadian Journal of Psychiatry 1994;39(2):74-84.
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
Bollini 1994
  • Bollini P, Pampallona S, Orza MJ, Adamas ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomised control trials. Psychological Medicine 1994;24:307-16.
Citrome 2011
Clarke 2002
  • Clarke M, Oxman AD (editors). Cochrane Reviewer's Handbook. Cochrane Database of Systematic Reviews 2002, issue 2.
Conley 1997
CPA 1998
  • Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie 1998;2 Suppl 43:25-40.
Davis 2003
De Oliveira 1996
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. 2000.
Divine 1992
Donner 2002
Duggan 2002
  • Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD001359.pub2]
Egger 1997
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: sulpiride versus placebo for schizophrenia 18/22 methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Emsley 1995
  • Emsley R, McCreadie R, Livingston M, De Smedt G, Lemmens P. Risperidone in the treatment of first-episode schizophrenic patients with schizophreniform disorder: a double blind study. Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia. 1995.
Endicott 1978
Gardner 2005
Geddes 1999
  • Geddes J. Royal College of Psychiatrists guidelines on for the care of those with schizophrenia. The Schizophrenia Trials Meeting; 1999 May 5-7; Stratford-upon-Avon, UK 1999.
Glazer 1998
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Guy 1976
  • Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
Hansen 1997
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hogarty 1973
Hogarty 1974
Hoyberg 1993
Hutton 2009
Huttunen 1995
Jadad 1996
  • Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavanagh DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
Jadad 1999
  • Jadad A. Meta-analysis making the same mistakes as trials. Proceedings of the 2nd Symposium on Systematic Reviews: Beyond the Basics; 1999 Jan 5-7; Oxford, UK. 1999.
Johnson 1993
Joy 2002
  • Joy C, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD003082.pub2]
Kane 1996
Kapur 1996
  • Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry 1996;153(7):948-50.
Kapur 1997
  • Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. American Journal of Psychiatry 1997;154(11):1525-9.
Kapur 1998
Kapur 2001
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Kennedy 2002
  • Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000440]
Kiivet 1995
Kudo 1999
  • Kudo Y, Nomura J, Ikawa G, Nakajima T, Saito M, Sakai T, et al. Clinical trial of quetiapine in schizophrenia-efficacy and tolerability of quetiapine: a comparative double-blind study with mosapramine in schizophrenic patients. Proceeding of the Annual Meeting of the World Psychiatric Association; 1999 Aug; Hamburg, Germany. 1999.
Leucht 1999
  • Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophrenia Research 1999;35:51-68.
Leucht 2005a
Leucht 2005b
Levy 1996
  • Levy RH. Sedation in acute and chronic agitation. Pharmacotherapy 1996;6(Part 2):152-9S, 166-8S.
Lieberman 1993
Marder 1998
  • Marder SR. Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry 1998;59(Suppl 3):21-5.
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Miller 1997
  • Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997;21(7):1059-94.
Milton 1995
Murasaki 1999
  • Murasaki M, Koyama T, Yamauchi T, Yagi MG, Ushijima S, Kamijima K. Clinical evaluation of quetiapine in schizophrenia-efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999.
Overall 1962
Peuskens 1997
Raschetti 1993
Reardon 1989
Rosenheck 2003
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
Schünemann 2011
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011:359-83.
Simpson 1970
Srisurapanont 2002
Thornley 2002
  • Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000284.pub2]
Thornley 1998
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
Whicher 2002
WHO 2011
  • World Health Organization. WHO Model Lists of Essential Medicines, 2011 www.who.int/medicines/publications/essentialmedicines/en/. (accessed 20 June 2013).
Williams 1999
  • Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care 1999;37 Suppl 4:81-6.
Zito 1998

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
RevMan 2011 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Waraich 2002
  • Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD001951; PUBMED: 12137638]